June 19, 2017 06:22 AM EDT

Clovis soars as a new round of PhIII Rubraca data looks promising — but roci scandal bites again with $142M settlement

John Carroll

Editor & Founder

Shares of Clovis Oncology soared 50% Monday morning, after the biotech reported a solid slate of progression-free survival data for its PARP drug Rubraca …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clovis soars as a new round of PhIII Rubraca data looks promising — but roci scandal bites again with $142M settlement

John Carroll

Editor & Founder

Sign up to read this article for free.

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Handful of 'unsupported' drug price increases added $800M to US costs, ICER claims

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

The key to faster, more impactful research? Put patients in the driver’s seat

Clo­vis soars as a new round of PhI­II Rubra­ca da­ta looks promis­ing — but ro­ci scan­dal bites again with $142M set­tle­ment

John Carroll

Editor & Founder

Sign up to read this article for free.

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set

Hand­ful of 'un­sup­port­ed' drug price in­creas­es added $800M to US costs, ICER claims

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Clovis soars as a new round of PhIII Rubraca data looks promising — but roci scandal bites again with $142M settlement

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Handful of 'unsupported' drug price increases added $800M to US costs, ICER claims

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

The key to faster, more impactful research? Put patients in the driver’s seat